Baxter International | BAX - Selling And Administration Expenses


Baxter International reported $735M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Abbott USD 3.6B 330M Jun/2026
AngioDynamics USD 36.57M 3.79M Sep/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 82.56M 1.99M Jun/2026
Baxter International USD 735M 7M Jun/2026
Becton, Dickinson and Co. USD 1.26B 48M Jun/2026
Boston Scientific USD 1.8B 22M Jun/2026
Cooper Companies USD 676.2M 303.1M Mar/2026
Dexcom USD 358.7M 9M Jun/2026
Edwards Lifesciences USD 561.2M 39M Jun/2026
Fresenius EUR 760M 17M Jun/2026
Globus Medical USD 286.82M 10.95M Jun/2026
Halozyme Therapeutics USD 57M 10.71M Jun/2026
ICU Medical USD 151.92M 2.64M Jun/2026
Inogen USD 43.77M 510K Jun/2024
Insulet USD 344.8M 27.6M Jun/2026
Integra LifeSciences USD 166.22M 12.01M Jun/2026
Intuitive Surgical USD 617.9M 4.6M Jun/2026
J&J USD 6.42B 381M Jun/2026
Laboratory Of America USD 577.2M 26.2M Jun/2026
Medtronic 2.96B 9M Dec/2025
Merit Medical Systems USD 129.23M 18.76M Jun/2026
Quest Diagnostics USD 529M 25M Jun/2026
Smith & Nephew USD 1.45B 29M Jun/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 111.64M 3.45M Jun/2026
Teleflex USD 213.52M 12.5M Jun/2026
Terumo JPY 109.7B 5.11B Jun/2026
Zimmer Biomet Holdings USD 911.6M 61.7M Jun/2026